Frances A. Shepherd

82.0k citations
684 papers · 53.1k · 22 hit papers · h-index 105

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 0.01%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies

Papers in

    • Lung Cancer Treatments and Mutations 326
    • Lung Cancer Diagnosis and Treatment 119
    • Lung Cancer Research Studies 154
    • Colorectal Cancer Treatments and Studies 61
    • Cancer Immunotherapy and Biomarkers 39

Frances A. Shepherd

662 papers receiving 51.3k citations

Frances A. Shepherd's Hit Papers

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC 2023 · 300 citations
3000+6+12Years since publication50010001.5k2.0k

Peers

Frances A. Shepherd
Comparison fields: 5 of 179
  • Pulmonary and Respiratory Medicine 28.5k
  • Oncology 23.7k
  • Cancer Research 5.6k
  • Hepatology 1.1k
  • Molecular Biology 9.9k
Replace Bruce E. Johnson with:
Bruce E. Johnson United States
Mark G. Kris United States
Jaffer A. Ajani United States
Roy S. Herbst United States
Kenneth R. Hess United States
Jaap Verweij Netherlands
Tony Mok Hong Kong
Joan H. Schiller United States
Robert J. Motzer United States
Toni K. Choueiri United States
Frances A. Shepherd relative to Bruce E. Johnson United States Bruce E. Johnson's profile →
Citations per field
00.5×1.6×
Bruce E. Johnson · 1×
Citations per year

Countries citing papers authored by Frances A. Shepherd

Since Specialization
Citations

This map shows the geographic impact of Frances A. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frances A. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frances A. Shepherd more than expected).

Fields of papers citing papers by Frances A. Shepherd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frances A. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frances A. Shepherd. The network helps show where Frances A. Shepherd may publish in the future.

Co-authors

The 25 scholars most cited alongside Frances A. Shepherd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frances A. Shepherd Line = papers co-authored together Frances A. Shepherd links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 684 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Hit paper breakdown →
20054412
2
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Hit paper breakdown →
20162453
3
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hit paper breakdown →
20041965
4
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Hit paper breakdown →
20081825
5
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Hit paper breakdown →
20001771
6
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Hit paper breakdown →
20051532
7
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Hit paper breakdown →
20051434
8
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Hit paper breakdown →
20091053
9
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Hit paper breakdown →
20081027
10
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
Hit paper breakdown →
1999734
11
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hit paper breakdown →
2016719
12
EGFR Mutations and Lung Cancer
Hit paper breakdown →
2011714
13
Non-small-cell lung cancer
Hit paper breakdown →
2011604
14
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Hit paper breakdown →
2009578
15
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Hit paper breakdown →
2008575
16
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Hit paper breakdown →
2016511
17
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Hit paper breakdown →
2016406
18 2007394
19 2009361
20 2010361

About Frances A. Shepherd

Frances A. Shepherd is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 684 papers that have together received 53.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (326 papers), Lung Cancer Research Studies (154 papers), Lung Cancer Diagnosis and Treatment (119 papers), Colorectal Cancer Treatments and Studies (61 papers), Cancer Genomics and Diagnostics (54 papers), Cancer Immunotherapy and Biomarkers (39 papers), Neuroendocrine Tumor Research Advances (38 papers) and Cancer therapeutics and mechanisms (30 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (28.5k citations), Oncology (23.7k citations), Cancer Research (5.6k citations), Hepatology (1.1k citations) and Molecular Biology (9.9k citations). Frances A. Shepherd has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Ming‐Sound Tsao, Lesley Seymour, Keyue Ding, Ronald Feld, William K. Evans, Geoffrey Liu, Natasha B. Leighl, Vera Hirsh, Gilda da Cunha Santos and Andrea Bezjak. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact